ERBB2 and breast cancer: The ongoing Phase II clinical trial (NCT03765983) investigates the investigational intervention GDC-0084 in combination with the FDA-approved targeted therapy trastuzumab for the treatment of HER2-positive breast cancer, specifically focusing on patients with brain metastases.